Jeil Pharm (002620) fair value: what the stock is really worth
As of Nov 12, 2026: fair value (intrinsic value) of Jeil Pharm stock KRW 15,569, price KRW 6,870, upside +126.6%, quality 50 out of 100. Rating: strongly undervalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 12, 2026.
How to read this chart
60‑month range 6,290 KRW – 24,969 KRW · fair‑value band 12,155 KRW – 20,259 KRW · the 6,870 KRW price screens below the 15,569 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 1 fiscal year is left out: there the valuation rested on only a fraction of the usual models. As of Nov 12, 2026.
Follow Jeil Pharm in your weekly email
Every Wednesday you see whether Jeil Pharm is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Jeil Pharma Holdings Inc manufactures and sells ingredients of drugs, incrementally modified drugs, and generic drugs in South Korea.
Show moreShow less
The company offers active pharmaceutical ingredients in the areas of antibiotics, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamines, as well as patch products.
It also provides finished dosage forms in the areas of anti-bacteria and anti-fungal, anti-virus, cardiovascular, endocrinology, neurology, gastrointestinal, urology, oncology, anti-histamine, rheumatology, respiratory, otolaryngological, heaptic, laxatives, and purgatives.
The company exports its products to approximately 40 countries in the Association of Southeast Asian Nations, Central and South America, Africa, etc. The company was founded in 1959 and is headquartered in Seoul, South Korea.
Stock analysis
Jeil Pharm (002620) currently trades at 6,870 KRW, while our model-based Fair Value estimate is 15,569 KRW, implying the stock looks roughly 56% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 27,657 KRW per share, and 15 of the 17 models we run sit above the 6,870 KRW price.
Bear case: the Asset-Based group reads lowest at 6,912 KRW, and 2 of the 17 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 12,155 KRW (bear) to 20,259 KRW (bull), the price of 6,870 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Jeil Pharm reported revenue of 658B KRW in FY2025 versus 763B KRW in FY2021, a compound −3.6%/yr. Reported net income was 14.6B KRW in FY2025.
Key figures
Market cap 105B KRW (≈ $79.4M) Micro · P/E ratio 12.5 · P/S ratio 0.17 · EPS (TTM) 549.45 KRW · Dividend yield 1.0% · Net margin 1.3% · Return on equity 5.6% · Return on assets (EBIT) 0.7% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 21 out of 100 (low confidence).
What moves the price
The share trades about 26% below its 52-week high and 9% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −26% fair-value upside, at 127%, 002620 screens cheaper than that median.
Fair Value models
Bear12,155 KRWFair Value 15,569 KRWBull20,259 KRW
Price 6,870 KRW · Upside +126.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (415.08 KRW per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.6/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−15.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.9%
Start year 2020 (pandemic). Over 10 years: +1.0% a year
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.5%
’11
’12
’15
’16
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +6.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year≈ +5.1%
Dividend (yield on the price)1.0%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.3% → 6%
⚠ Base effect: the rate starts in the earnings trough around 2020 (starting value 745 per share, median 69900 in 2017 to 2018). It measures the recovery from the trough, not lasting growth.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score50 · Below median
Fair Value upside+126.6% · Top 25%
Profitability
Return on equity (12 months)5.6% · Below median
Return on assets4.0% · Above median
Net margin (12 months)3.2% · Below median
Operating margin (12 months)−6.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)3.1% · Below median
Dividend yield (12 months)1.0% · Below median
Balance sheet
Debt / equity0.05× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Jeil Pharm Fair Value". https://www.fairvalue-calculator.com/stock/002620
Frequently asked questions
Is Jeil Pharm (002620) overvalued or undervalued?
As of Nov 12, 2026, our model estimates a fair value of 15,569 KRW versus a price of 6,870 KRW, about +127% upside (undervalued).
What is the fair value of 002620?
Our model-based fair value for Jeil Pharm is 15,569 KRW (as of Nov 12, 2026), built from audited fundamentals. The current price: 6,870 KRW.
What is the quality score of 002620?
Jeil Pharm has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Jeil Pharm (002620)?
Our model-based price target is the fair value of 15,569 KRW (as of Nov 12, 2026) from 17 valuation models. Cautious scenario 12,155 KRW, optimistic scenario 20,259 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Jeil Pharm stock forecast for 2026?
Our models put fair value at 15,569 KRW, about +127% upside versus a price of 6,870 KRW (undervalued). Cautious scenario 12,155 KRW, optimistic scenario 20,259 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Jeil Pharm (002620)?
Jeil Pharm reported trailing-twelve-month revenue of about 631B KRW (latest available figure, as of Nov 12, 2026).
Does Jeil Pharm pay a dividend?
Jeil Pharm currently shows a dividend yield of 1.02% relative to its recent price (as of Nov 12, 2026).
How much is the dividend of Jeil Pharm (002620) and when is the ex-dividend date?
Jeil Pharm pays a dividend of 70.00 KRW per share a year, a dividend yield of 1.0%. The last ex-dividend date was Dec 29, 2025. A dividend has been paid every year since at least 1996. The payout ratio is 12.7% of earnings. Our assessment: Watch coverage. The dividend isn’t fully covered by free cash flow or earnings, part of it is funded from reserves or debt. Fine for now, but worth watching: if it stays uncovered, the dividend could be cut.
What is the intrinsic value of Jeil Pharm (002620)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Jeil Pharm it is 15,569 KRW per share (as of Nov 12, 2026), against a price of 6,870 KRW. It is the blended result of 17 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Jeil Pharm stock overvalued or undervalued in 2026?
As of Nov 12, 2026, 002620 trades below its calculated fair value: price 6,870 KRW, fair value 15,569 KRW, a gap of about +127% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 002620?
No. The price is what the market pays today (6,870 KRW); the fair value is what the company's own numbers justify (15,569 KRW). For Jeil Pharm the two are 8,699 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Jeil Pharm worth?
The market values Jeil Pharm at about 105B KRW (market capitalisation, as of Nov 12, 2026). Per share that is 6,870 KRW; our models calculate a fair value of 15,569 KRW per share.
What do the bullish and bearish scenarios say about 002620?
Our models span a range for Jeil Pharm: cautious scenario 12,155 KRW, base 15,569 KRW, optimistic 20,259 KRW per share (as of Nov 12, 2026, price 6,870 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 002620?
Jeil Pharm trades at a price-to-earnings ratio of 12.5 (as of Nov 12, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 15,569 KRW is built from several models across several years. Other multiples: P/B 0.3, P/S 0.4, EV/EBITDA 4.6.
How solid is the balance sheet of Jeil Pharm (002620)?
Balance-sheet figures for Jeil Pharm (as of Nov 12, 2026): return on equity 5.6%, debt of 0.05 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is 002620 from its 52-week high?
Jeil Pharm trades at 6,870 KRW, about 26% below its 52-week high of 9,280 KRW and 9% above the low of 6,290 KRW (as of Nov 12, 2026). Distance from the high says nothing about value: that is what the fair value of 15,569 KRW is for.
Which stocks are comparable to Jeil Pharm?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Jeil Pharm stock attractive at the current price?
The data as of Nov 12, 2026: price 6,870 KRW, calculated fair value 15,569 KRW (+127%), Quality Score 50/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 002620 calculated?
We run Jeil Pharm through 17 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 15,569 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0% above its aggregate fair value. Jeil Pharm currently trades 56% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Jeil Pharm (002620)?
The closing price on Nov 12, 2026 was 6,870 KRW. Our model-based fair value is 15,569 KRW, about +127% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Jeil Pharm right now?
The price is below even our cautious bear case (12,155 KRW). The market is more pessimistic than our downside scenario. Solid quality (50/100) at a price below fair value, the discount is the argument here, not the business quality.
Key figures of Jeil Pharm
How large is the market capitalisation of Jeil Pharm (002620)?
The market capitalisation of Jeil Pharm is 105B KRW (≈ $79.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Jeil Pharm (002620)?
The price-to-sales ratio of Jeil Pharm is 0.17 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Jeil Pharm (002620)?
Earnings per share at Jeil Pharm are 549.45 KRW (price ÷ EPS = P/E 12.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Jeil Pharm (002620)?
The dividend yield of Jeil Pharm is 1.0% (payout 12.7%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Jeil Pharm (002620)?
The net margin of Jeil Pharm is 1.3% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Jeil Pharm (002620)?
The return on equity (ROE) of Jeil Pharm is 5.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Jeil Pharm (002620)?
On an EBIT basis the return on assets of Jeil Pharm is 0.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Jeil Pharm (002620)?
The operating margin of Jeil Pharm is −6.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Jeil Pharm (002620)?
Revenue at Jeil Pharm is growing +3.1% versus a year earlier (3y avg −6.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Jeil Pharm (002620)?
Earnings per share at Jeil Pharm are growing −52.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Jeil Pharm (002620) generate?
The free cash flow of Jeil Pharm is −8.9B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Jeil Pharm (002620) carry?
The net debt of Jeil Pharm is 110B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Jeil Pharm in the live analysis
One click puts Jeil Pharm on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 12, 2026